Clinical Pathological Characteristics and Prognosis of Multigene Co-Mutations in Elderly Patients With Non-Small Cell Lung Cancer: A Retrospective Analysis

Overview

Journal Clin Med Insights Oncol

Publisher Sage Publications

Specialty Oncology

Date 2023 Nov 30

PMID 38033742

Authors

Wanjing Li

Fangqun Chang

Hao Zhang

Furong Meng

Zhangyan Ke

Yanbei Zhang

Affiliations

Soon will be listed here.

Abstract

Background: With the development and wide application of next-generation sequencing (NGS), multiple-gene mutations related to lung cancer are detected using this technology. Notably, even multigene concomitant mutations (co-mutations), which occur at a relatively low incidence, can be detected more effectively using NGS. It is well-known that the percentages of non-small cell lung cancer (NSCLC) in the elderly lung cancer population are also gradually increasing, while its prognosis is hard and the quality of long-term survival is poor. This study aimed at investigating the common clinicopathologic features of multigene co-mutations for better evaluating the prognosis of elderly NSCLC patients.

Methods: A total of 464 NSCLC patients were divided into 3 groups according to the types of gene mutation, whose clinical data were retrospectively analyzed.

Results: In total, 38.36% (178/464) of NSCLC patients were in the nonmutation group, 50% in the single-gene mutation group, and 11.64% in the multigene co-mutation group. Nonmutation, single-gene mutation, and co-mutation groups were all prone to occur in male adenocarcinoma patients ( < .05). EGFR gene mutation rates were the highest in the single-gene mutation and co-mutation groups (54.31% and 24.35%). In the co-mutation group, the incidence of EGFR/PIK3CA, LK/KRAS, and EGFR/MET co-mutations was the highest (16.67%, 11.11%, and 7.41%). ALK/HER2/MET, EGFR/HER2/MET, and EGFR/HER2/MET/ROS1 multiple-gene co-mutations were, respectively, found in 1 case, and the multigene co-mutation patients commonly had a worse median progression-free survival (PFS) than that of single-gene mutation (7.13 vs 12.34 months, = .013).

Conclusion: With the application of NGS, the detectable rates of gene co-mutation are increasingly high in elderly patients with NSCLC, which mainly occurs in male adenocarcinoma patients commonly with poor PFS. It will be critically necessary to conduct multigene detections by NGS for directing targeted therapy of elderly NSCLC patients.

Citing Articles

Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report.

Peng G, Song H, Chen W World J Clin Oncol. 2024; 15(7):945-952.

PMID: 39071469 PMC: 11271735. DOI: 10.5306/wjco.v15.i7.945.

References

Cheng Y, Ma L, Liu Y, Zhu J, Xin Y, Liu X . Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors. Lung Cancer. 2020; 145:63-70. DOI: 10.1016/j.lungcan.2020.04.004. View

Wang H, Zhang M, Tang W, Ma J, Wei B, Niu Y . Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis. Cancer Biol Ther. 2018; 19(8):687-694. PMC: 6067862. DOI: 10.1080/15384047.2018.1450115. View

Peng M, Weng Y, Liu H, Yang G, Yao Y, Han G . Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations. Biomed Res Int. 2018; 2018:7181368. PMC: 5822926. DOI: 10.1155/2018/7181368. View

Hong S, Gao F, Fu S, Wang Y, Fang W, Huang Y . Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(5):739-742. PMC: 5885210. DOI: 10.1001/jamaoncol.2018.0049. View

Deng H, Liu J, Duan X, Liu Y . The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma. Pathol Res Pract. 2018; 214(3):450-454. DOI: 10.1016/j.prp.2017.09.008. View

Gao S, Li N, Wang S, Zhang F, Wei W, Li N . Lung Cancer in People's Republic of China. J Thorac Oncol. 2020; 15(10):1567-1576. DOI: 10.1016/j.jtho.2020.04.028. View

Leonetti A, Facchinetti F, Tiseo M . Upfront osimertinib in -mutated non-small cell lung cancer: is brain still a sanctuary?. Ann Transl Med. 2019; 6(Suppl 2):S110. PMC: 6330596. DOI: 10.21037/atm.2018.11.69. View

Chen H, Liu M, Dai Z, Li S, Luo Y, Wang Y . Concomitant genetic alterations are associated with response to targeted therapy in patients with lung adenocarcinoma. Transl Lung Cancer Res. 2020; 9(4):1225-1234. PMC: 7481595. DOI: 10.21037/tlcr-20-679. View

Chen P, Liu Y, Wen Y, Zhou C . Non-small cell lung cancer in China. Cancer Commun (Lond). 2022; 42(10):937-970. PMC: 9558689. DOI: 10.1002/cac2.12359. View

10.

Barnet M, OToole S, Horvath L, Selinger C, Yu B, Ng C . EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2016; 12(3):585-590. DOI: 10.1016/j.jtho.2016.09.001. View

11.

Kim Y, Lee B, Shim J, Lee S, Park W, Choi Y . Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. J Thorac Oncol. 2018; 14(2):193-202. DOI: 10.1016/j.jtho.2018.10.150. View

12.

Chang S, Lai Y, Chang C, Huang L, Chen S, Tan K . Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. Transl Oncol. 2019; 12(11):1425-1431. PMC: 6700434. DOI: 10.1016/j.tranon.2019.07.008. View

13.

Canale M, Petracci E, Delmonte A, Bronte G, Chiadini E, Ludovini V . Concomitant Mutation Confers Worse Prognosis in -Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. J Clin Med. 2020; 9(4). PMC: 7230306. DOI: 10.3390/jcm9041047. View

14.

Zhang W, Li Y, Lyu J, Shi F, Kong Y, Sheng C . An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma. Cancer Sci. 2021; 113(3):891-903. PMC: 8898732. DOI: 10.1111/cas.15254. View

15.

Thai A, Solomon B, Sequist L, Gainor J, Heist R . Lung cancer. Lancet. 2021; 398(10299):535-554. DOI: 10.1016/S0140-6736(21)00312-3. View

16.

Gibert J, Clave S, Hardy-Werbin M, Taus A, Rocha P, Longaron R . Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma. Lung Cancer. 2019; 140:42-45. DOI: 10.1016/j.lungcan.2019.12.003. View

17.

Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S . Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med. 2019; 8(6):2858-2866. PMC: 6558647. DOI: 10.1002/cam4.2183. View

18.

Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E . Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010; 17(3):889-97. DOI: 10.1245/s10434-009-0808-7. View

19.

Won J, Keam B, Koh J, Cho H, Jeon Y, Kim T . Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol. 2014; 26(2):348-54. DOI: 10.1093/annonc/mdu530. View

20.

Gainor J, Varghese A, Ou S, Kabraji S, Awad M, Katayama R . ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013; 19(15):4273-81. PMC: 3874127. DOI: 10.1158/1078-0432.CCR-13-0318. View